LIPAD - LRRK2 International Parkinson's Disease Study (LIPAD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04214509 |
Recruitment Status : Unknown
Verified February 2020 by Meike Kasten, University of Luebeck.
Recruitment status was: Recruiting
First Posted : January 2, 2020
Last Update Posted : February 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Parkinson's Disease and Parkinsonism |
Study Type : | Observational |
Estimated Enrollment : | 4000 participants |
Observational Model: | Other |
Time Perspective: | Cross-Sectional |
Official Title: | LIPAD - LRRK2 International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study |
Actual Study Start Date : | January 20, 2020 |
Estimated Primary Completion Date : | December 31, 2021 |
Estimated Study Completion Date : | December 31, 2021 |

Group/Cohort |
---|
PD + LRRK2
Patients with LRRK2-associated Parkinson's syndrome
|
no PD + LRRK2
Participants with LRRK2-mutations but without Parkinson's symptoms
|
no PD + no LRRK2
Participants without mutations and without Parkinson's symptoms
|
PD+ other than LRRK2
Parkinson patients with mutations in other genes than LRRK2
|
PD+ no LRRK2
Patients with idiopathic Parkinson's disease
|
- Epidemiology of LRRK2-positive patients [ Time Frame: 2 years ]Description of the frequency of all important clinical signs and symptoms including non-motor signs and factoring in the most important influencing factors such as sex, disease duration, and medication. We will report raw and corrected frequencies with 95% confidence intervals.
- Analysis of penetrance of LRRK2 mutations [ Time Frame: 2 years ]Penetrance rates (the proportion of individuals with LRRL2 mutation who exhibit clinical symptoms of Parkinson's disease) and phenotypes, and will try to predict penetrance in logistic regression models and quantify the influence of different factors impacting on penetrance.
- Analysis of expressivity of LRRK2 mutations [ Time Frame: 2 years ]We will analyze expressivity (the degree in which a genotype is phenotypically expressed) of LRRK2 mutations. We will first define meaningful categories using our phenotypic data and then proceed to identify influencing factors.
Biospecimen Retention: Samples With DNA
Blood and urine samples will be biochemically analysed to determine factors leading to incomplete penetrance in LRRK2 positive carriers and biomarkers of Parkinson's disease.
In blood samples DNA and DNA methylation, RNA and proteins will be analysed. Urine samples will be analysed using NGS-based sequencing of the mitochondrial genome and search for mitochondrial DNA deletions.
Dust will be analysed toxicologically.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Informed consent is obtained from the participant.
- The participant is clinically diagnosed with Parkinson's disease or the individual is a family member of a participant with LRRK2 parkinsonism or is a member of a high risk population with an early PD onset.
- The participant is equal to or older than 18 years old.
Exclusion Criteria:
- Inability to provide informed consent.
- The participant is not suffering from Parkinson's disease or the individual is not a family member of a participant with LRRK2 parkinsonism or is not a member of a high risk population.
- The participant is younger than 18 years old.
- Previously enrolled in the study.
- Participant in custody.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04214509
Contact: Meike Kasten, Prof. Dr. | +4945131017518 | lipad.ropad@neuro.uni-luebeck.de |
Germany | |
Institute of Neurogenetics | Recruiting |
Luebeck, Schelswig-Holstein, Germany, 23562 | |
Contact: Tatiana Usnich, MD, PhD +4945131017518 | |
Contact: Nathalie Schell, MD +4945131017518 |
Principal Investigator: | Christine Klein, Prof. Dr. | Institute of Neurogenetics, University of Luebeck | |
Principal Investigator: | Meike Kasten, Prof. Dr. | Department of Psychiatry, University of Luebeck |
Responsible Party: | Meike Kasten, Prof., University of Luebeck |
ClinicalTrials.gov Identifier: | NCT04214509 |
Other Study ID Numbers: |
LIPAD |
First Posted: | January 2, 2020 Key Record Dates |
Last Update Posted: | February 27, 2020 |
Last Verified: | February 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | The Plan will be defined at later stages. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
genetic Parkinson's disease LRRK2 |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |